Oncotarget

Clinical Research Papers:

A phase II open-label multicenter study of gefitinib in combination with irradiation followed by chemotherapy in patients with inoperable stage III non-small cell lung cancer

Antonin Levy, Etienne Bardet, Benjamin Lacas, Jean-Pierre Pignon, Julien Adam, Ludovic Lacroix, Xavier Artignan, Pierre Verrelle and Cécile Le Péchoux _

PDF  |  HTML  |  How to cite

Oncotarget. 2017; 8:15924-15933. https://doi.org/10.18632/oncotarget.12741

Metrics: PDF 1869 views  |   HTML 2563 views  |   ?  


Abstract

Antonin Levy1,2,3, Etienne Bardet4, Benjamin Lacas5,6, Jean-Pierre Pignon5,6, Julien Adam7, Ludovic Lacroix7, Xavier Artignan8,10, Pierre Verrelle9 and Cécile Le Péchoux1

1 Department of Radiation Oncology, Gustave Roussy, Université Paris-Saclay, Institut Thoracique d’Oncologie (IOT), Villejuif, France

2 INSERM U1030, Molecular Radiotherapy, Gustave Roussy, Université Paris-Saclay, Villejuif, France

3 Univ Paris Sud, Université Paris-Saclay, Le Kremlin-Bicêtre, France

4 Department of Medical Oncology, Institut de Cancérologie de l’Ouest, Nantes, France

5 Gustave Roussy, Université Paris-Saclay, Department of Biostatistics and Epidemiology, Villejuif, France

6 INSERM U1018, CESP, Université Paris-Sud, Université Paris-Saclay, Villejuif, France

7 Department of Medical Biology and Pathology, Translational Research Laboratory and Biobank (UMS3655 CNRS / US23 INSERM), INSERM Unit U981, Villejuif, France

8 Department of Radiation Oncology, University Hospital Grenoble, Grenoble, France

9 Department of Radiation Oncology, Centre Jean Perrin, Clermont-Ferrand, France

10 Department of Radiation Oncology, St Grégoire Hospital, St Grégoire, France

Correspondence to:

Cécile Le Péchoux, email:

Keywords: iressa, thoracic radiotherapy, lung cancer, phase II trial

Received: July 06, 2016 Accepted: October 12, 2016 Published: October 18, 2016

Abstract

Background: Gefitinib is an oral EGFR tyrosine kinase inhibitors which may act as a radiosensitizer.

Patients and Methods: This phase II study evaluated the efficacy of gefitinib 250 mg once daily in combination with thoracic radiotherapy (66 Gy in 6.5 weeks, 2 Gy/day, 5 fractions/week) followed by consolidation chemotherapy (IV cisplatin and vinorelbine) as first line treatment in a population of unselected stage IIIB NSCLC patients according to EGFR mutation status.

Results: Due to a low accrual rate in this study, the sample size (n = 50) was not reached. Sixteen patients were included in four centers, 50% had adenocarcinoma and 75% were male. Genomic alterations (7 patients studied) retrieved TP53 mutation in 2 patients and no EGFR mutation. Four weeks after radiotherapy, 3 patients (19%) had a partial response, 6 (38%) had a stable disease, and 7 had a progression (44%). Median overall survival was 11 months and median progression-free survival was 5 months. At the time of the last contact, 5 patients (31%) were still alive. Main toxicities were gastrointestinal (81%), cutaneous (81%), general (56%), and respiratory (50%). There were 12>G3 adverse events in 7 (47%) patients, and there was one toxic-death during the concomitant period due to an interstitial pneumonitis. There were two possible adverse events-related deaths during the chemotherapy period (pulmonary embolism (n = 1) and sudden death after the administration of the 3rd course of chemotherapy (n = 1)).

Conclusion: The benefit of Gefitinib-RT could not be confirmed due to premature trial discontinuation. Further evaluation is required, especially in patients with EGFR mutated NSCLC.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 12741